Press Releases

Near-term Focus On Carotid and DES Products, Streamlined Operations   BOSTON, MA – January 5, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced its revenue and cash position for the 2014 fourth quarter, ended December 31. Total revenues were approximately $900,000, which represented… Read More

MASTER I and MASTER II Pooled Data Show Statistically Significant Mortality Benefit  CARENET 30 Day DW-MRI Data Demonstrates Significant Reduction in New Ischemic Ipsilateral Lesions BOSTON, MA – December 15, 2014 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced results from two important clinical trials…. Read More

Master II 30 day data to be presented December 15th at the ICI Meeting 2014, Tel-Aviv  Announced first pre-clinical implant with partner DES platform BOSTON, MA – November 12, 2014 – InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in stent embolic protection systems (“EPS”), today announced its financial and operating results for… Read More

BOSTON, MA – November 7, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in stent Embolic Protection Systems (EPS), today announced the closing of its registered direct offering of approximately 6.2 million shares of common stock and warrants to purchase up to approximately 3.1 million shares of common stock at a price of… Read More

BOSTON, MA – November 5, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in stent embolic protection systems, announced today that it will release its financial results for the third quarter ended September 30, 2014 on Wednesday, November 12th.   The Company will host a conference call at 4:30 p.m…. Read More

BOSTON, MA – November 4, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in stent Embolic Protection Systems (EPS), today announced that it has entered into a definitive agreement to sell approximately 6.2 million shares of common stock and warrants to purchase up to approximately 3.1 million shares of common stock in a… Read More

Validation of manufacturing process changes for the MGuard Prime EPS BOSTON, MA – October 29, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in Embolic Protection Systems (EPS), today announced that the FDA has approved the Company’s submitted IDE amendment for certain manufacturing process changes to the MGuard Prime EPS that were proposed… Read More

MGuard Prime commercial re-launch complete in direct markets   Drug Eluting Stent (DES) program advances in development with partners — MASTER II trial to suspend enrollment to support DES and Carotid Opportunities — Investor conference call this morning at 8:30 a.m. ET   BOSTON, MA – October 14, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT:… Read More

BOSTON, MA – October 1, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (EPS), today announced that it has recorded the first commercial sales of the CGuard™ carotid EPS. The Company accelerated the limited market release (LMR) of the CGuard based on strong interest created by the recent positive… Read More

CARENET Trial data presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference, September 16, 2014,showed 0% MACE at 30 Days   BOSTON, MA – September 18, 2014 — InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), will host a live webinar and Q&A to discuss the positive results of… Read More